Pimecrolimus cream 1% in erosive oral lichen planus- a prospective randomized double-blind vehicle-controlled study
Authors:
- 1 October 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 159 (4) , 936-941
Abstract
Erosive oral lichen planus (EOLP) is a T-cell mediated inflammatory disease leading to severe pain and impairment. As current therapies are of limited efficacy, application of calcineurin inhibitors is considered to be a potential option. To investigate the efficacy of pimecrolimus cream 1% (Elidel) compared with vehicle cream in the treatment of EOLP. Twenty patients were enrolled in a prospective, double-blind, randomized, vehicle-controlled trial and assigned to either pimecrolimus or vehicle group. Study medication was applied for 30 days followed by 30 days of observation without therapy. In case of unresponsiveness, treatment was continued for 30 days with open-label pimecrolimus. EOLP was monitored on days 0, 30 and 60. Safety was assessed by patient documentation, measurement of pimecrolimus levels and blood counts. Within 30 days erosions cleared completely in seven of 10 patients treated with pimecrolimus and in two of 10 patients treated with vehicle. The clinical EOLP 'composite score' including mucosal erosions and pain sensation was significantly reduced in the pimecrolimus-treated group compared with vehicle (P = 0.025). In the three of 10 patients not responding to pimecrolimus, EOLP cleared after an additional 30 days of treatment with pimecrolimus. Following termination of the therapy, sustained remission of EOLP was detected in 83% of patients demonstrating long-lasting effects of pimecrolimus treatment. No severe adverse events were observed. In five patients pimecrolimus blood levels were detected, all of which stayed below 4 ng mL(-1). Pimecrolimus cream 1% effectively treats EOLP with long-lasting therapeutic effects and is therefore a promising therapeutic option for EOLP.Keywords
This publication has 31 references indexed in Scilit:
- Lack of Association between Exposure to Topical Calcineurin Inhibitors and Skin Cancer in AdultsDermatology, 2007
- Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic DermatitisJournal of Investigative Dermatology, 2007
- Discovery of Topical Calcineurin Inhibitors and Pharmacological Profile of PimecrolimusInternational Archives of Allergy and Immunology, 2006
- Current controversies in oral lichen planus: Report of an international consensus meeting. Part 1. Viral infections and etiopathogenesisOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2005
- Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trialBritish Journal of Dermatology, 2005
- Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trialBritish Journal of Dermatology, 2005
- Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and ImmunologyJournal of Allergy and Clinical Immunology, 2005
- Treatment of erosive oral lichen planus with topical tacrolimusJournal of Dermatological Treatment, 2004
- Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planusBritish Journal of Dermatology, 2004
- Pimecrolimus Identifies a Common Genomic Anti-inflammatory Profile, is Clinically Highly Effective in Psoriasis and is Well ToleratedJournal of Investigative Dermatology, 2002